{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:44:15Z","timestamp":1786999455236,"version":"build-2736575974"},"reference-count":58,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"unspecified","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Acta Neuropsychiatr."],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Non-adherence and negative attitudes towards medication are major problems in treating psychotic disorders. Cytochrome P450 2D6 (CYP2D6) contributes to the metabolism of aripiprazole and risperidone, and variations in CYP2D6 activity may affect treatment response or adverse effects. However, the impact of these variations on adherence and medication attitudes is unclear. This study investigates the relationships between CYP2D6 phenotype, self-reported adherence, adverse effects, and attitudes among aripiprazole and risperidone users. The study analysed data from the SUPER-Finland cohort of 10,474 adults with psychotic episodes, including 1,429 aripiprazole and 828 risperidone users. The Attitudes towards Neuroleptic Treatment (ANT) questionnaire assessed adherence and adverse effects in all patients, while medication-related attitudes were examined in a subgroup of 1,000 participants. Associations between CYP2D6 phenotypes and outcomes were analysed using logistic regression and beta regression in aripiprazole and risperidone groups separately. Among risperidone users, we observed no association between CYP2D6 phenotypes and adherence, adverse effects, or attitudes. Similarly, we found no link between adherence and CYP2D6 phenotypes among aripiprazole users. However, aripiprazole users with the ultrarapid CYP2D6 phenotype had more adverse effects (OR = 1.71, 95 % CI 1.03\u20132.90,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.041). Among aripiprazole users, CYP2D6 ultrarapid phenotype was associated with less favourable attitudes towards antipsychotic treatment (\u03b2 = \u22120.48,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.023). These findings provide preliminary evidence that the ultrarapid CYP2D6 phenotype is associated with increased adverse effects and negative attitudes towards antipsychotic medication among aripiprazole users. CYP2D6 phenotype did not influence adherence, adverse effects, or attitudes among risperidone users.\n                  <\/jats:p>","DOI":"10.1017\/neu.2025.11","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T09:12:00Z","timestamp":1742893920000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":1,"title":["Influence of CYP2D6 phenotype on adherence, adverse effects, and attitudes in aripiprazole and risperidone users"],"prefix":"10.1017","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2001-4322","authenticated-orcid":false,"given":"Elina","family":"Hietala","sequence":"first","affiliation":[{"name":"Tampere University"},{"name":"Vanha Vaasa Hospital"},{"name":"Department of Psychiatry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anssi","family":"Solismaa","sequence":"additional","affiliation":[{"name":"Tampere University"},{"name":"Pirkanmaa Hospital District"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku","family":"L\u00e4hteenvuo","sequence":"additional","affiliation":[{"name":"Niuvanniemi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari V.","family":"Ahola-Olli","sequence":"additional","affiliation":[{"name":"University of Helsinki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"H\u00e4kkinen","sequence":"additional","affiliation":[{"name":"Niuvanniemi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimmo","family":"Suokas","sequence":"additional","affiliation":[{"name":"Tampere University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkki","family":"Isomets\u00e4","sequence":"additional","affiliation":[{"name":"University of Helsinki and Helsinki University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaana","family":"Suvisaari","sequence":"additional","affiliation":[{"name":"Finnish Institute for Health and Welfare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuula","family":"Kiesepp\u00e4","sequence":"additional","affiliation":[{"name":"Hospital District of Helsinki and Uusimaa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Holm","sequence":"additional","affiliation":[{"name":"Finnish Institute for Health and Welfare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"Tiihonen","sequence":"additional","affiliation":[{"name":"Niuvanniemi Hospital"},{"name":"Karolinska Institutet"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jouko","family":"L\u00f6nnqvist","sequence":"additional","affiliation":[{"name":"Finnish Institute for Health and Welfare (THL)"},{"name":"University of Helsinki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarmo","family":"Hietala","sequence":"additional","affiliation":[{"name":"University of Turku"},{"name":"Turku University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asko","family":"Wegelius","sequence":"additional","affiliation":[{"name":"University of Helsinki and Helsinki University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaisla","family":"Lahdensuo","sequence":"additional","affiliation":[{"name":"Mehil\u00e4inen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willehard","family":"Haaki","sequence":"additional","affiliation":[{"name":"University of Turku"},{"name":"Turku University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"study SUPER-Finland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6891-2266","authenticated-orcid":false,"given":"Olli","family":"Kampman","sequence":"additional","affiliation":[{"name":"Tampere University"},{"name":"Department of Psychiatry"},{"name":"Pirkanmaa Hospital District"},{"name":"University of Turku"},{"name":"Ume\u00e5 University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"S0924270825000110_ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2020.06.007"},{"key":"S0924270825000110_ref50","doi-asserted-by":"publisher","DOI":"10.1177\/1403494812456637"},{"key":"S0924270825000110_ref47","doi-asserted-by":"publisher","DOI":"10.1097\/01.fpc.0000239974.69464.f2"},{"key":"S0924270825000110_ref46","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbad120"},{"key":"S0924270825000110_ref44","first-page":"E225","article-title":"Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study","volume":"2","author":"Pringsheim","year":"2014","journal-title":"Canadian Medical Association Journal Open"},{"key":"S0924270825000110_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2024.04.001"},{"key":"S0924270825000110_ref41","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12590"},{"key":"S0924270825000110_ref3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-011711-113247"},{"key":"S0924270825000110_ref22","first-page":"473","article-title":"Schizophrenia","volume":"399","author":"Jauhar","year":"2022","journal-title":"The Lancet (British edition)"},{"key":"S0924270825000110_ref34","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbv167"},{"key":"S0924270825000110_ref51","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13208"},{"key":"S0924270825000110_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2022.04.008"},{"key":"S0924270825000110_ref37","doi-asserted-by":"publisher","DOI":"10.1016\/0920-9964(94)00051-9"},{"key":"S0924270825000110_ref52","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10081224"},{"key":"S0924270825000110_ref49","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4914(01)01986-4"},{"key":"S0924270825000110_ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2354"},{"key":"S0924270825000110_ref38","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2006.8.1\/wmillas"},{"key":"S0924270825000110_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2015.11.020"},{"key":"S0924270825000110_ref31","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.176.3.217"},{"key":"S0924270825000110_ref55","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S343211"},{"key":"S0924270825000110_ref9","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12692"},{"key":"S0924270825000110_ref29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-070710"},{"key":"S0924270825000110_ref53","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.17091001"},{"key":"S0924270825000110_ref15","unstructured":"Flockhart, D (2003) Cytochrome P450 drug interaction table, \u2026 . iupui. edu\/flockhart\/table. htm [Accessed 2005 Apr 8], pp. 1\u20132. Available at: https:\/\/drug-interactions.medicine.iu.edu\/MainTable.aspx (Accessed: 19 May 2024)."},{"key":"S0924270825000110_ref39","doi-asserted-by":"publisher","DOI":"10.1211\/jpp.58.7.0001"},{"key":"S0924270825000110_ref20","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13945"},{"key":"S0924270825000110_ref10","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sby058"},{"key":"S0924270825000110_ref40","doi-asserted-by":"crossref","unstructured":"Nyanyiwa, S , Peters, K and Murphy, G (2022) A scoping review: treatment attitudes and adherence for adults with schizophrenia, Journal of clinical nursing. England: Wiley Subscription Services, Inc, pp. 3060\u20133075, 10.1111\/jocn.16219.","DOI":"10.1111\/jocn.16219"},{"key":"S0924270825000110_ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2149"},{"key":"S0924270825000110_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"S0924270825000110_ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1965-1"},{"key":"S0924270825000110_ref13","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/23.4.637"},{"key":"S0924270825000110_ref32","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-021-03037-0"},{"key":"S0924270825000110_ref57","unstructured":"WHO (2022) WHOCC - use of ATC\/DDD, WHO collaborating centre for drug statistics methodology, Available at: https:\/\/www.whocc.no\/use_of_atc_ddd\/ (Accessed:16 December 2022)."},{"key":"S0924270825000110_ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-023-02586-x"},{"key":"S0924270825000110_ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.771"},{"key":"S0924270825000110_ref56","unstructured":"U.S. Food & Drug Administration (FDA) (2023) For healthcare professionals | FDA\u2019s examples of drugs that interact with CYP enzymes and transporter systems, Available at: https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems?utm_source=chatgpt.com (Accessed: 9 February 2025)."},{"key":"S0924270825000110_ref36","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3679"},{"key":"S0924270825000110_ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(99)00204-2"},{"key":"S0924270825000110_ref19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"S0924270825000110_ref18","first-page":"1","article-title":"Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in finnish individuals with a psychotic disorder","volume":"12","author":"H\u00e4kkinen","year":"2022","journal-title":"The Pharmacogenomics Journal"},{"key":"S0924270825000110_ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2004.06.031"},{"key":"S0924270825000110_ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(02)00030-6"},{"key":"S0924270825000110_ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.01.035"},{"key":"S0924270825000110_ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s12199-008-0043-z"},{"key":"S0924270825000110_ref26","doi-asserted-by":"publisher","DOI":"10.1176\/ps.2010.61.3.272"},{"key":"S0924270825000110_ref43","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2014.16.4\/jpouget"},{"key":"S0924270825000110_ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"S0924270825000110_ref6","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2022.1"},{"key":"S0924270825000110_ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-023-01347-3"},{"key":"S0924270825000110_ref14","unstructured":"Finnish Medicines Agency Fimea and Social Insurance Institution (2021) Finnish statistics on medicines 2020. Available at: https:\/\/urn.fi\/URN:NBN:fi-fe2021122162437 (Accessed: 26 January 2022)."},{"key":"S0924270825000110_ref17","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S42735"},{"key":"S0924270825000110_ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.06.035"},{"key":"S0924270825000110_ref4","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbp094"},{"key":"S0924270825000110_ref16","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n1012"},{"key":"S0924270825000110_ref58","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1425-9"},{"key":"S0924270825000110_ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2018.06.005"},{"key":"S0924270825000110_ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30088-4"}],"container-title":["Acta Neuropsychiatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924270825000110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:54:07Z","timestamp":1759848847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924270825000110\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":58,"alternative-id":["S0924270825000110"],"URL":"https:\/\/doi.org\/10.1017\/neu.2025.11","relation":{},"ISSN":["0924-2708","1601-5215"],"issn-type":[{"value":"0924-2708","type":"print"},{"value":"1601-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"\u00a9 The Author(s), 2025. Published by Cambridge University Press on behalf of Scandinavian College of Neuropsychopharmacology","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e54"}}